SAN DIEGO (EGMN) - Induction therapy with obinutuzumab, a bioengineered CD20 inhibitor, induced a slightly higher overall response rate in induction therapy than did rituximab in patients with relapsed, CD20-positive indolent B-cell non-Hodgkin's lymphoma, investigators reportedat the annual meeting of the American Society of Hematology.According to independent radiology reviewers who were blinded to treatment type, the overall response rate - a composite of complete responses (CR), CR-unconfirmed...